Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
AB Sciex
FOCUS DIAGNOSTICS, INC.

Gene Fusion Identified as Cause of Rare Thyroid Cancer

By Labmedica International staff writers
Posted on 03 Apr 2014
Image: Photomicrograph of tall cell variant of papillary thyroid carcinoma metastases in the axillary lymph nodes (Photo courtesy of Dr. Arvind Krishnamurthy).
Image: Photomicrograph of tall cell variant of papillary thyroid carcinoma metastases in the axillary lymph nodes (Photo courtesy of Dr. Arvind Krishnamurthy).
Analysis of tumor and whole blood DNA by whole genome sequencing has identified the fusion of two genes as the genetic driver in an aggressive tall cell variant of papillary thyroid cancer.

Recent advances in the treatment of cancer have focused on targeting genomic aberrations with selective therapeutic agents, but in radioiodine resistant aggressive papillary thyroid cancers, there remain few effective therapeutic options.

Scientists at the Translational Genomics Research Institute (Phoenix, AZ, USA) obtained a blood and tumor sample from the patient, a 62-year-old man who underwent multiple operations for papillary thyroid cancer and whose metastases progressed despite standard treatments. Whole genome sequencing of tumor and white blood cell DNA was conducted by a commercial vendor according to their methods using photolithographically patterned high-density nanoarrays onto which palindrome-promoted coils of single-stranded DNA are absorbed (Complete Genomics; Mountain View, CA, USA).

Tumor paraffin blocks were submitted to ARUP Laboratories (Salt Lake City, UT, USA) for validation by reverse transcriptase polymerase chain reaction (RT-PCR) in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. A comparison of the tumor DNA to the patient's normal DNA found 57 mutations in 55 genes of the cancer genome. The investigators also found a rearrangement between two genes. This translocation and fusion of the echinoderm microtubule associated protein like 4 (EML4) gene and the anaplastic lymphoma receptor tyrosine kinase (ALK) gene, was identified as the genetic driver of the patient's cancer.

Michael J. Demeure, MD, the study's principal investigator and lead author, said, “This is the first report of the whole genome sequencing of a papillary thyroid cancer, in which we identified an EML4-ALK translocation. This is important because we have a drug that can target this fusion and treat the patient. This patient's tumor did not harbor more well-known gene mutations that are associated with most thyroid cancers. These findings suggest that this tumor has a distinct oncogenesis, or the genetic cause of cancer.” The study was published on March 15, 2014, in the World Journal of Surgery.

Related Links:

Translational Genomics Research Institute 
Complete Genomics
ARUP Laboratories



VIRCELL
DiagCor Bioscience
ADVANCED INSTRUMENTS
comments powered by Disqus
Life Technologies

Channels

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Pathology

view channel
Image: Histopathology of increased endomysial connective tissue from a patient with Duchenne Muscular Dystrophy. Necrotic fibers arrowed (Photo courtesy of Washington University in St. Louis).

New Partnership Designed to Automate Dystrophin Measurement

A developer of innovative ribonucleic acid (RNA)-based therapeutics, Sarepta Therapeutics, Inc. ( Cambridge, MA, USA), and a leading tissue-based companion diagnostics firm, Flagship Biosciences LLC (Boulder,... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.